Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.

Pterygium is an ocular disease in which the conjunctival tissue invades the cornea. When the pterygium tissue reaches the pupillary region, the visual function of the patient is affected. Currently, surgical removal is the only effective treatment.

Bibliometric analysis and visualization of the research on the relationship between RNA methylation and immune cell infiltration in tumors.

Background: This research endeavors to delve into the research hotspots and trends concerning RNA methylation and tumor immune cells through the application of bibliometric analysis and visualization techniques.

Methods: A comprehensive search in WoSCC (2014-2023) for RNA methylation and tumor immune cell articles/reviews was conducted. Bibliometric analysis and visualization employed CiteSpace, Bibliometric, and VOSviewer tools.

The NCR1 transporter is an antimalarial target that exports cholesterol from the parasite's plasma membrane.

Malaria, a devastating parasitic infection, is the leading cause of death in many developing countries. Unfortunately, the most deadliest causative agent of malaria, , has developed resistance to nearly all currently available antimalarial drugs. The Niemann-Pick type C1-related (PfNCR1) transporter has been identified as a druggable target, but its structure and detailed molecular mechanism are not yet available.

Occurrence and resolution of freediving-induced pulmonary syndrome in breath-hold divers: an online survey of lung squeeze incidents.

Introduction: Breath-hold divers occasionally surface with signs of fluid accumulation and/or bleeding in air-filled spaces. This constellation of symptoms, recently termed 'freediving induced pulmonary syndrome', is thought to come from immersion pulmonary oedema and/or barotrauma of descent and is colloquially termed a 'squeeze'. There is limited understanding of the causes, diagnosis, management, and return to diving recommendations after a squeeze.

Systematic review of exercise for the treatment of pediatric metabolic dysfunction-associated steatotic liver disease.

Background & Aims: Steatotic liver disease affects approximately 1 in 10 children in the U.S. and increases the risk of cirrhosis, diabetes, and cardiovascular disease.